eligibility_summary
Eligibility: Age ≥70 with newly diagnosed, untreated DLBCL, ≥1 measurable lesion (≥15 mm), life expectancy >3 months, adequate organ function (ALT/bilirubin/creatinine <3×ULN, LVEF ≥50%, SpO2 >90% on room air), consent. Exclude severe hepatic/renal dysfunction, symptomatic heart disease (NYHA ≥2), uncontrolled infection, CNS DLBCL, vascular embolism history, other malignancies, need for systemic steroids, or psychological barriers to consent/participation.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: Orelabrutinib (oral, covalent Bruton tyrosine kinase inhibitor, small molecule) blocks B‑cell receptor signaling (BTK→NF‑κB). Pomalidomide (IMiD) binds cereblon to degrade IKZF1/3, enhancing T/NK‑cell cytotoxicity and exerting anti‑proliferative/anti‑angiogenic effects. Rituximab (anti‑CD20 monoclonal antibody) depletes CD20+ B cells via ADCC/CDC. Responders receive Pro‑miniCHOP‑like: add cyclophosphamide (alkylator DNA crosslinker), doxorubicin or liposomal doxorubicin (anthracycline Topo II inhibitor), vindesine (vinca microtubule inhibitor), and dexamethasone (glucocorticoid). Non‑responders get R‑miniCHOP‑like (without orelabrutinib/pomalidomide). Maintenance: pomalidomide. Targets/pathways: CD20+ malignant B cells, BCR/BTK/NF‑κB, cereblon/IKZF1/3 with T/NK activation, DNA damage (alkylation/Topo II), microtubules, glucocorticoid receptor–mediated apoptosis.